Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the early management of patients with acute Ischemic Stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2018;49(3):e46–110. https://doi.org/10.1161/STR.0000000000000158.

Article  PubMed  Google Scholar 

Berge E, Whiteley W, Audebert H, et al. European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute Ischaemic Stroke. Eur Stroke J. 2021;6(1):I–LXII. https://doi.org/10.1177/2396987321989865.

Article  PubMed  PubMed Central  Google Scholar 

Heran M, Lindsay P, Gubitz G, et al. Canadian Stroke Best practice recommendations: acute stroke management, 7(th) edition practice guidelines update, 2022. Can J Neurol Sci. 2024;51(1):1–31. https://doi.org/10.1017/cjn.2022.344.

Article  PubMed  Google Scholar 

Chinese Society of Cardiology of Chinese Medical A, Editorial Board of Chinese Journal of C. [2019 Chinese Society of Cardiology (CSC) guidelines for the diagnosis and management of patients with ST-segment elevation myocardial infarction]. Zhonghua Xin Xue Guan Bing Za Zhi. 2019;47(10):766–83. https://doi.org/10.3760/cma.j.issn.0253-3758.2019.10.003.

Fan G, Wu XG, Jiao WP, et al. Safety and efficacy of intracoronary recombinant human prourokinase administration in patients with acute myocardial infarction and ST-segment elevation: a meta-analysis of randomized controlled trials. Exp Ther Med. 2023;25(1):40. https://doi.org/10.3892/etm.2022.11739.

Article  CAS  PubMed  Google Scholar 

Wu Y, Fu X, Feng Q, et al. Efficacy and safety of intracoronary prourokinase during percutaneous coronary intervention in treating ST-segment elevation myocardial infarction patients: a randomized, controlled study. BMC Cardiovasc Disord. 2020;20(1):308. https://doi.org/10.1186/s12872-020-01584-0.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jiang W, Xiong X, Du X, et al. Safety and efficacy study of prourokinase injection during primary percutaneous coronary intervention in acute ST-segment elevation myocardial infarction. Coron Artery Dis. 2021;32(1):25–30. https://doi.org/10.1097/MCA.0000000000000898.

Article  PubMed  Google Scholar 

Xiong Y, Hao M, Pan Y, et al. Rationale and design of ProUrokinase in Mild IsChemic strokE (PUMICE): a multicentre, prospective, randomised, open-label, blinded-endpoint controlled trial. Stroke Vasc Neurol. 2024;9(6):715–22. https://doi.org/10.1136/svn-2023-002673.

Article  PubMed  Google Scholar 

Song H, Wang Y, Ma Q, et al. Efficacy and safety of recombinant human prourokinase in the treatment of acute ischemic stroke within 4.5 hours of stroke onset: a phase 3 randomized clinical trial. JAMA Netw Open. 2023;6(7):e2325415. https://doi.org/10.1001/jamanetworkopen.2023.25415.

Article  PubMed  PubMed Central  Google Scholar 

Hao CH, Ding WX, Sun Q, et al. Effect of human recombinant prourokinase(rhpro-UK) on thromboembolic stroke in rats. Eur J Pharmacol. 2018;818:429–34. https://doi.org/10.1016/j.ejphar.2017.11.026.

Article  CAS  PubMed  Google Scholar 

Hao C, Ding W, Xu X, et al. Effect of recombinant human prourokinase on thrombolysis in a rabbit model of thromboembolic stroke. Biomed Rep. 2018;8(1):77–84. https://doi.org/10.3892/br.2017.1013.

Article  CAS  PubMed  Google Scholar 

Takano K, Carano RA, Tatlisumak T, et al. Efficacy of intra-arterial and intravenous prourokinase in an embolic stroke model evaluated by diffusion-perfusion magnetic resonance imaging. Neurology. 1998;50(4):870–5. https://doi.org/10.1212/wnl.50.4.870.

Article  CAS  PubMed  Google Scholar 

Song H, Wang Y, Ma Q, et al. Efficacy and safety of recombinant human prourokinase in acute ischemic stroke: a phase IIa randomized clinical trial. Transl Stroke Res. 2022;13(6):995–1004. https://doi.org/10.1007/s12975-022-01012-9.

Article  CAS  PubMed  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71. https://doi.org/10.1136/bmj.n71.

Article  PubMed  PubMed Central  Google Scholar 

Saver JL, Chaisinanunkul N, Campbell BCV, et al. Standardized nomenclature for modified Rankin scale global disability outcomes: consensus recommendations from stroke therapy academic industry roundtable XI. Stroke. 2021;52(9):3054–62. https://doi.org/10.1161/STROKEAHA.121.034480.

Article  PubMed  Google Scholar 

Palaiodimou L, Katsanos AH, Turc G, et al. Tenecteplase versus alteplase in acute ischemic stroke within 4.5 hours: a systematic review and meta-analysis of randomized trials. Neurology. 2024;103(9):e209903. https://doi.org/10.1212/WNL.0000000000209903.

Article  CAS  PubMed  Google Scholar 

Huang J, Zheng H, Zhu X, et al. Tenecteplase versus alteplase for the treatment of acute ischemic stroke: a meta-analysis of randomized controlled trials. Ann Med. 2024;56(1):2320285. https://doi.org/10.1080/07853890.2024.2320285.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sterne JAC, Savovic J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366: l4898. https://doi.org/10.1136/bmj.l4898.

Article  PubMed  Google Scholar 

Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60. https://doi.org/10.1136/bmj.327.7414.557.

Article  PubMed  PubMed Central  Google Scholar 

Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34. https://doi.org/10.1136/bmj.315.7109.629.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Song H, Wang Y, Ma Q, et al. Thrombolysis with recombinant human prourokinase 4.5–6 h after acute ischemic stroke: a phase IIa, randomized, and open-label multicenter clinical trial. CNS Drugs. 2024;38(1):67–75. https://doi.org/10.1007/s40263-023-01051-2.

Article  CAS  PubMed  Google Scholar 

Li S, Gu HQ, Feng B, et al. Safety and efficacy of intravenous recombinant human prourokinase for acute ischaemic stroke within 4.5 h after stroke onset (PROST-2): a phase 3, open-label, non-inferiority, randomised controlled trial. Lancet Neurol. 2025;24(1):33–41. https://doi.org/10.1016/S1474-4422(24)00436-8.

Article  CAS  PubMed  Google Scholar 

Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363(9411):768–74. https://doi.org/10.1016/S0140-6736(04)15692-4.

Article  PubMed  Google Scholar 

Group ISTc, Sandercock P, Wardlaw JM, et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet. 2012;379(9834):2352–63. https://doi.org/10.1016/S0140-6736(12)60768-5.

Article  CAS  Google Scholar 

Fulton RL, Lees KR, Bluhmki E, et al. Selection for delayed intravenous alteplase treatment based on a prognostic score. Int J Stroke. 2015;10(1):90–4. https://doi.org/10.1111/j.1747-4949.2012.00943.x.

Article  PubMed  Google Scholar 

Emberson J, Lees KR, Lyden P, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet. 2014;384(9958):1929–35. https://doi.org/10.1016/S0140-6736(14)60584-5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Campbell BCV, Ma H, Ringleb PA, et al. Extending thrombolysis to 4.5–9 h and wake-up stroke using perfusion imaging: a systematic review and meta-analysis of individual patient data. Lancet. 2019;394(10193):139–47. https://doi.org/10.1016/S0140-6736(19)31053-0.

Article  PubMed  Google Scholar 

Burgos AM, Saver JL. Evidence that tenecteplase is noninferior to alteplase for acute ischemic stroke: meta-analysis of 5 randomized trials. Stroke. 2019;50(8):2156–62. https://doi.org/10.1161/STROKEAHA.119.025080.

Article  CAS  PubMed  Google Scholar 

Amiri H, Bluhmki E, Bendszus M, et al. European cooperative acute stroke study-4: extending the time for thrombolysis in emergency neurological deficits ECASS-4: ExTEND. Int J Stroke. 2016;11(2):260–7. https://doi.org/10.1177/1747493015620805.